The Nasdaq Now: Acquisition News and Rumors Send Eloqua, Arris Group, and Illumina Soaring

By Sterling Wong  DEC 20, 2012 12:20 PM

Research In Motion was also up on the day.

 


MINYANVILLE ORIGINAL The stock market was little changed in mid-Thursday trading as investors ignored macro economic data and continued to keep a close ‘fiscal cliff’ watch.
 
"While negotiations on the fiscal cliff have stalled over the last couple of days, the likelihood of going past year-end without any resolution of the fiscal cliff has not increased, in our view," said Goldman Sachs economists, according to TheStreet. "This is due in part to progress made to date in negotiations between President Obama and Speaker Boehner. However, it is also because it has become increasingly possible that if those negotiations fail, a fallback plan could be passed to avert at least some of the fiscal restraint scheduled for 2013, with remaining issues potentially revisited in early 2013."
 
The Nasdaq Composite (INDEXNASDAQ:.IXIC) was down 0.12% to 3,040.62 points on average trading volume of 716.49 million as of 12:06 p.m. EST.
 
Newly-public Eloqua (NASDAQ:ELOQ) soared 31.36% to $23.54 on news that Oracle (NASDAQ:ORCL) (-0.19%) would acquire the cloud-based marketing automation platform for some $871 million, or $23.50 per share.
 
THQ (NASDAQ:THQI) also rallied 25.80% to $0.45. Yesterday, the video game maker collapsed 73% after announcing that it would file for bankruptcy.
 
Illumina (NASDAQ:ILMN) jumped 8.04% to $56.36 after it was reported that Roche Holding (PINK:RHHBY) (-1.44%) may have agreed to buy the company at a price 48% higher than its first failed bid. Swiss newspaper L’Agefi said that the two parties may have agreed to a $66-per-share, or $8.1 billion, bid for Illumina that might be publically announced in the first half of 2013. The US maker of DNA sequencing equipment originally rejected Roche’s $6.7 billion bid last April.
 
Arris Group (NASDAQ:ARRS) improved 5.16% to $15.29 on news that it would be buying Motorola Mobility’s home business from Google (NASDAQ:GOOG) (+0.18%) for $2.4 billion.
 
Ahead of an eagerly-awaited fiscal third-quarter earnings report, investors were cautiously optimistic about Research In Motion (NASDAQ:RIMM), sending the stock up 0.73% to $13.73.
 
Amicus Therapeutics (NASDAQ:FOLD) crashed 45.38% to $3.15 after it, along with GlaxoSmithKline (NYSE:GSK) (+0.38%), reported poor late-stage study results for its Fabry disease treatment.
 
Allscripts Healthcare Solutions (NASDAQ:MDRX) also plunged 13.95% to $9.19 after abandoning plans for a sale. The company, which sells systems that allow hospitals and physicians to share patient records electronically, instead ousted CEO Glen Tullman and announced plans to continue to be run as an independent entity under new management.
 
Bed Bath & Beyond (NASDAQ:BBBY) slid 8.06% to $55.42 after reporting fourth-quarter and full-year outlooks that fell beneath analysts’ expectations. The stock was also cut to Neutral from Buy by Bank of America.

Twitter: @sterlingwong
No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.